The China Economic Information Service (CEIS) Industrial Insight and Industrial Data Service Platform recently released the Top 50 Rankings of China Biomanufacturing Industrial City Competitiveness in 2025. Changsha ranked sixth with a comprehensive score of 87.82 points.

Changsha is a major growth engine for the biomanufacturing industry in central and western parts of China. The city has leveraged its three "Double First-Class" universities and 25 national key laboratories, to establish a collaborative framework where "basic research is conducted at universities, pilot-scale conversion takes place on platforms, and large-scale production occurs in industrial parks." Focusing on four cutting-edge fields such as gene and cell diagnostics and therapy, and synthetic biology, the city has fostered a differentiated industrial cluster.

In 2025, Changsha's biomedical industrial cluster joined seven other provincial clusters in being designated as part of Hunan Province's advanced manufacturing clusters. As the primary hub for Changsha's biopharmaceutical sector, the Liuyang Economic and Technological Development Zone and the Xiangjiang New Area have continuously refined industrial chain layouts, established innovation platforms, and optimized the industrial ecosystem in recent years. The two areas have attracted a batch of high-quality enterprises spanning medicine R&D, medical device manufacturing, and healthcare services, forming a synergistic "R&D-production-application" industrial pattern. Liuyang's high-end chemical API industrial cluster was selected as a national-level characteristic industrial cluster for SMEs. In 2025, Changsha's biomedical industrial cluster emerged victorious in the provincial competition for advanced manufacturing clusters.

At the policy level, Changsha provides comprehensive support throughout the entire lifecycle from R&D and commercialization to industrialization—while enhancing customs clearance efficiency and leveraging industrial funds to safeguard industrial development. Highlighting "expanding product varieties, enhancing quality, and building brands," the city is propelling the industry toward mid-to-high-end segments. Over the past three years, a total of 17 biopharmaceutical enterprises have been cultivated and recognized as provincial-level benchmark enterprises. Jiuzhitang was recommended for competing China's renowned consumer brands and has been included in the 2025 list.

This article is from the Hunan Provincial Government www.enghunan.gov.cn.

Translator: Yu Jiangjiang

Chinese sources: hunantoday